From April 23, 2009, through April 10, 2010, it is estimated that pandemic (H1N1) 2009 virus caused ≈61 million cases of influenza (range 43--89 million cases), ≈270,000 related hospitalizations (range 195,000--403,000 hospitalizations), and ≈12,500 deaths (range 8,900--18,300 deaths) in the United States ([@R1]). Even before the impact was fully known, the Centers for Disease Control and Prevention (CDC) recommended prompt empiric treatment with influenza antiviral drugs, principally the neuraminidase-inhibiting influenza antiviral drugs oseltamivir and zanamivir, of persons with suspected or confirmed influenza and who also met \>1 of the following conditions: 1) illness that required hospitalization; 2) progressive, severe, or complicated illness, regardless of previous health status; and 3) risk for severe disease (e.g., patients with asthma, neurologic and neurodevelopmental conditions; chronic lung or heart disease; blood, endocrine, kidney, liver, and metabolic disorders; pregnancy; and those who were old or young) ([@R2]). The primary goal of these recommendations was to reduce the number and severity of pandemic (H1N1) 2009 cases, especially hospitalizations.

We present estimates of the number of pandemic (H1N1) 2009--related hospitalizations, by age group, averted because of use of antiviral drugs given to treat clinical cases of influenza. These results can be used by public health policy makers to plan and prepare for the next pandemic. For example, these estimates can be used to help evaluate the policy option of replenishing state and federal influenza antiviral drug stockpiles

Methods
=======

We developed a spreadsheet-based model to calculate the number of pandemic (H1N1) 2009--related hospitalizations averted because of treatment with the neuraminidase-inhibiting influenza antiviral drugs oseltamivir and zanamivir ([Technical Appendix](#SD1){ref-type="local-data"}). The risk for hospitalization (and thus potential benefit from antiviral drugs) differed by age groups ([@R1]). Therefore, we estimated the reduced number of hospitalizations separately for 3 groups: persons 0--17 years of age, 18--64 years of age, and \>65 years of age. We calculated the hospitalizations averted by using the following general equation: no. hospitalizations averted (by age group) = \[no. prescriptions written -- estimated no. written for prophylaxis, stockpiling, or incomplete adherence to drug regimen\] × age group--specific risk for hospitalizations caused by pandemic (H1N1) 2009 × age group--specific effectiveness of drugs in preventing hospitalizations.

Prescriptions Filled
--------------------

We used the number of prescriptions filled for these drugs for weeks ending April 24, 2009, through March 26, 2010 ([Table 1](#T1){ref-type="table"}), collected from the IMS Health (IMS) Xponent proprietary prescription database (IMS Health, Norwalk, CT, USA) ([@R3]). This database contains all retail prescriptions filled from a representative sample of 35,000 (73%) of ≈50,000 US-based retail pharmacies, including independent pharmacies, chain pharmacies, pharmacies in discount outlets, pharmacies in food stores, mail order pharmacies, and pharmacy benefit management companies. IMS then proportionately extrapolates their data on the basis of populations served by the included pharmacies to provide weekly estimates of all prescriptions filled in the United States for these drugs. The Xponent database does not track prescriptions filled by in-hospital pharmacies. Therefore, in-hospital prescriptions are not part of our calculations.

###### Number of pandemic (H1N1) 2009 cases versus number of influenza antiviral prescriptions filled during pandemic (H1N1) 2009 outbreak, United States, April 24, 2009--March 26, 2010\*

  Week†           Mid-level estimate of cases‡   Filled influenza antiviral prescriptions             
  --------------- ------------------------------ ------------------------------------------ --------- -----------
  2009 Apr--Jul   3,052,768                      1,243,827                                  69,513    1,313,340
  2009 Aug        1,605,760                      342,386                                    11,645    354,031
  35              626,256                        146,282                                    5,097     151,379
  36              1,675,630                      234,211                                    7,171     241,382
  37              1,302,846                      265,626                                    7,892     273,518
  38              1,508,514                      331,060                                    8,735     339,795
  39              2,319,691                      383,759                                    9,981     393,740
  40              4,461,542                      435,546                                    11,625    447,171
  41              6,549,205                      471,323                                    11,226    482,549
  42              7,120,298                      527,362                                    11,218    538,580
  43              6,297,210                      671,741                                    12,046    683,787
  44              5,899,647                      640,887                                    9,306     650,193
  45              5,013,181                      537,781                                    6,338     544,119
  46              3,350,286                      386,569                                    4,863     391,432
  47              1,767,166                      273,092                                    3,039     276,131
  48              1,020,606                      152,482                                    1,857     154,339
  49              804,901                        133,998                                    1,782     135,780
  50              646,358                        99,565                                     1,348     100,913
  51              612,204                        88,718                                     1,338     90,056
  52              619,080                        64,807                                     1,010     65,817
  1               418,803                        56,569                                     1,009     57,578
  2               520,390                        50,642                                     981       51,651
  3               516,958                        50,326                                     1,057     51,307
  4               356,400                        44,770                                     1,048     45,827
  5               493,448                        43,757                                     1,211     44,805
  6               322,623                        42,474                                     1,251     43,685
  7               312,327                        43,809                                     1,228     45,060
  8               281,986                        47,146                                     1,487     48,374
  9               245,707                        48,671                                     1,494     50,158
  10              288,215                        47,261                                     1,587     48,755
  11              225,448                        33,867                                     1,043     34,910
  12              312,575                        26,072                                     730       26,802
  Total           60,548,030                     7,966,386                                  211,156   8,177,542

\*IMS Health Xponent database ([@R3]) includes 57,544 oseltamivir prescriptions and 877 zanamivir prescriptions for week 53. Because the Centers for Disease Control and Prevention only reports 52 weeks for 2009, we removed week 53 from the IMS data set (IMS, Norwalk, CT, USA). †Estimates of cases for April--August 2009 are not available on a weekly basis. ‡Mid-level weekly cases estimated from ([@R1]) and [www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm](http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm).

The IMS Xponent database captures all filled prescriptions related to influenza antiviral drugs within its sample pharmacies. However, it does not identify the source of the drugs. During 2009, there were 2 main potential supplies for the antiviral drugs---the regular commercial supply system and state and federal government-maintained drug stockpiles. The IMS database does not track medications dispensed from public domains, such as public health departments. Furthermore, the federal and state stockpiles of antiviral drugs were meant to supplement the commercial supply chain in times of drug shortages anticipated to occur during a pandemic emergency.

As of August 2010, the estimated total amount of antiviral drugs managed by states throughout the pandemic was 38 million treatment regimens. This estimate includes antiviral drugs purchased by states (26 million treatment regimens) plus ≈12 million treatment regimens distributed early in the pandemic to states from the CDC Strategic National Stockpile (SNS). Preliminary reports from state public health departments to the CDC show that most SNS product was either retained by the health departments or deployed at the local level (to dispensing sites such as drug stores and health departments). Sites received directions that the SNS-provided supplies were to be dispensed if commercial supplies could not keep up with demand or used to treat uninsured or underinsured persons who could otherwise not afford treatment. Preliminary data reported to CDC through SNS show that minimum quantities of stockpiled antiviral drugs were actually dispensed to patients. Because the commercial supply chain for antiviral drugs remained relatively robust, most states did not need to use stockpiled antiviral drugs. Therefore, we did not include any estimates of impact on antiviral drugs dispensed from these government stockpiles.

Prescriptions by Age Group
--------------------------

IMS collects for filled prescriptions deidentified data regarding age of patient from the pharmacy systems. We thus divided the total number of prescriptions given into 3 age groups (0--17 years, 18--64 years, \>65 years) by using age-specific data from IMS that covered prescriptions written for oseltamivir from October 9, 2009, through March 26, 2010. The percentages were as follows: 0--17 years, 38.6%; 18--64 years, 53.4%; \>65 years, 5.3% ([Table 2](#T2){ref-type="table"}). Note that ≈3% of prescriptions filled during this period did not have the age of the patient recorded. Therefore, we did not include those prescriptions in our analysis.

###### Input values used to estimate influenza antiviral drug--related reduction in hospitalizations during pandemic (H1N1) 2009 outbreak in the United States, April 24, 2009--March 26, 2010

  Input                                                                                                    Initial value                                              Sources
  -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------
  Distribution of prescriptions by patient age group, y\*                                                                                                             IMS Health Xponent database ([@R3])
  0--17                                                                                                    38.6%                                                      
  18--64                                                                                                   53.4%                                                      
  \>65                                                                                                     5.3%                                                       
  Prescriptions filled for prophylaxis†                                                                    10%                                                        Assumption: Some prescriptions were written to prevent infection and disease without presentation of symptoms.
  Prescriptions for patients who failed to adhere to drug regimen or used for personal stockpiles          20%                                                        Assumption: Not all patients will adhere with the drug regimen as prescribed. Also, some prescriptions were for personal stockpiles
  Antiviral drug effectiveness against hospitalization, by age group, y‡                                   Literature review (see [Table 3](#T3){ref-type="table"})   
  0--17                                                                                                    22%--32%                                                   
  18--64                                                                                                   34%--50%                                                   
  \>65                                                                                                     30%--50%                                                   
  Median (range) risk for hospitalization, given pandemic (H1N1) 2009--related illness, by age group, y§   Reed et al. ([@R4])                                        
  0--17                                                                                                    0.0038 (0.00314--0.00428)                                  
  18--64                                                                                                   0.00496 (0.0041--0.00558)                                  
  \>65                                                                                                     0.0155 (0.0128--0.0174)                                    

\*Age group--based distribution of prescriptions based on IMS (IMS Health, Norwalk, CT, USA) that covered prescriptions written for oseltamivir (only) from October 9, 2009, through March 26, 2010. †These inputs were subjected to sensitivity analyses (see [Table 4](#T4){ref-type="table"}). ‡Effectiveness estimate assumes that the patient follows the drug regimen, i.e., these estimates do not allow for those who do not take the complete course. Failure to follow prescribed drug regimen was assumed to have 0% effect on reducing risk of hospitalization. This assumption was accounted for in a separate input. §Risk of per-person hospitalization, given symptomatic illness caused by pandemic (H1N1) 2009 virus.

Prescriptions over Time
-----------------------

We plotted the total number of prescriptions filled per week, from the IMS database, against the weekly number of estimated pandemic cases for April 24, 2009, through March 26, 2010. Estimates of cases for April through the end of July 2009 are not available on a weekly basis. Thus, all cases were combined into a single estimate for that period ([@R1]). We combined for the same period all filled prescriptions and directly compared cases and prescriptions. A notable divergence in the correlation between plots of cases and prescriptions over time would indicate the possibility of prescriptions being filled for reasons other than the immediate treatment of influenza-related illness (e.g., stockpiling or use for prophylaxis).

Percentage of Prescriptions Written for Prophylaxis
---------------------------------------------------

We assumed in the absence of any data that 10% of all prescriptions for these antiviral drugs were written for prophylaxis. This assumption was subject to sensitivity analyses (described below). We further assumed that such prescriptions essentially had no impact on reduction of hospitalizations ([Table 2](#T2){ref-type="table"}).

Adherence to Drug Regimen and Stockpiling
-----------------------------------------

We also assumed that a total of 20% of all prescriptions were for either personal stockpiles (i.e., not written for a clinically ill patient at time of prescription) or patients who did not sufficiently follow the recommended drug regimen so that the prescription had no impact on risk of hospitalization caused by nonadherence ([Table 2](#T2){ref-type="table"}). A study conducted in the United Kingdom during the (H1N1) 2009 pandemic found that 76%--80% of the patients did complete the full course of prescribed antiviral drugs ([@R5]). Another study among schoolchildren in London, UK, that examined adherence among those offered oseltamivir for prophylaxis found that 89% actually took \>1 dose and 66% of this group completed (or said they would complete) a full 10-day prophylaxis course ([@R6]). One of the drug effectiveness studies that we reviewed (discussed below) and used for model input values asked patients to self-record adherence; it found that ≈90% of enrolled patients were fully compliant ([@R7]). Our assumption that 20% of prescriptions were for either stockpiling or nonadherence was subject to sensitivity analyses (described below).

This allowance for nonadherence also acts as a proxy for those who may have started the treatment too late. To maximize drug effectiveness in alleviating the duration of symptoms, it is recommended that antiviral drug treatment start \<48 hours after onset of clinical symptoms ([@R2]).

Risk for Hospitalization Given Clinical Case of Pandemic (H1N1) 2009
--------------------------------------------------------------------

We used the risk for hospitalization by age group, given clinical illness caused by pandemic (H1N1) 2009, from Reed et al. ([@R4]) ([Table 2](#T2){ref-type="table"}). We identified 17 published studies that evaluated the effectiveness of neuraminidase inhibitors given influenza-induced clinical illness ([@R7],[@R8]--[@R21]; [Table 3](#T3){ref-type="table"}). Although many studies were random placebo-controlled trials, the studies did not use hospitalizations averted as a measured endpoint ([@R13]*,*[@R15]*--*[@R17]). We identified only 4 studies that specifically evaluated the impact of the antiviral drugs on risk for hospitalization, given clinical illness. One study provided an estimate of 50% reduction in the probability of influenza-specific hospitalizations (no confidence interval was published) ([@R7]). Three retrospective studies, using health insurance claims data, reported effectiveness in reducing hospitalizations (any cause) that ranged from 22% to 59%, with some variation by age ([@R8]*--*[@R10]). For each age group, we used lower and upper estimates of effectiveness, from a lower estimate of 22% reduction for children 0--17 years to an upper estimate of 50% for adults ([Table 2](#T2){ref-type="table"}).

###### Literature review of effectiveness of neuraminidase inhibitors in preventing influenza-related hospitalizations\*

  Drug                      Study type                                                                                                                           Population                                                                                                                                       Reduction in hospitalization point estimate (95% CI)       Reference
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------- ---------------------------------
  Zanamivir                 Randomized, double-blind, placebo-controlled trial                                                                                   455 patients residing in Australia, New Zealand, and South Africa age \>12 y with influenza-like symptoms of \<36 hours' duration                NA                                                         ([@R14])
  Oseltamivir               Open-label, multicenter international study                                                                                          1,426 patients (age range 12--70 y) seeking treatment \<48 h after onset of influenza symptoms                                                   NA                                                         ([@R15])
  Oseltamivir               Retrospective cohort analysis                                                                                                        The oseltamivir and untreated control groups each included 36,751 eligible patients                                                              22%; HR 0.78 (0.67--0.91)                                  ([@R8]); claims data
  Oseltamivir               Retrospective cohort study                                                                                                           Oseltamivir and untreated propensity matched control groups each included 45,751 eligible patients                                               30% any cause; OR 0.71 (0.62--0.83)                        ([@R9]); insurance claims data
  Zanamivir                 Randomized, double-blind studies in 38 centers in North America and 32 centers in Europe during the 1994--95 influenza season        417 adults with influenza-like illness of \<48 hours\' duration were randomly assigned to 1 of 3 treatments                                      NA                                                         ([@R16])
  Amantadine/ rimantadine   Two randomized, double-blind, placebo-controlled trials                                                                              ≈80 patients with laboratory-documented influenza A virus (H3N2) illness \<2 days\' duration                                                     NA                                                         ([@R13])
  Oseltamivir               Combined analysis of 10 prospective, placebo controlled, double-blind trials                                                         3,564 persons (age range 13--97 y) with influenza-like illness enrolled in 10 placebo-controlled, double-blind trials of oseltamivir treatment   59% any cause reduction; 50% influenza, at risk patients   ([@R7])
  Zanamivir                 Retrospective pooled analysis of data; all studies were randomized, double-blind, and placebo-controlled with 21--28 day follow-up   2,751 patients were recruited; of these, 321 (12%) were considered high risk and 154 were randomized to receive zanamivir                        NA                                                         ([@R17])
  Zanamivir                 Randomized, double-blind, placebo-controlled trial in primary care and hospital clinics                                              356 patients age \>12 y were recruited within 2 d of onset of typical influenza symptoms                                                         NA                                                         ([@R12])
  Zanamivir                 Pooled analyses of secondary endpoints                                                                                                                                                                                                                                                NA                                                         ([@R18])
  Oseltamivir               Randomized controlled trial                                                                                                          726 healthy nonimmunized adults with febrile influenza-like illness of \<36 hours' duration                                                      NA                                                         ([@R19])
  Oseltamivir               Retrospective cohort study                                                                                                           9,090 patients with diabetes and influenza                                                                                                       30% any cause; RR 0.70 (0.52--0.94)                        ([@R10]); insurance claims data
  Oseltamivir               Retrospective cohort study                                                                                                           The oseltamivir and untreated control groups each included 36,751 eligible patients, 50% with a claim for oseltamivir, 50% without               38%; RR 0.62 (0.52--0.74)                                  ([@R11]); insurance claims data
  Oseltamivir               Double-blind, stratified, randomized, placebo-controlled, multicenter trial                                                          Healthy adults (age range 18--65 y) who sought treatment \<36 h after onset of influenza symptoms                                                NA                                                         ([@R20])
  Oseltamivir               Randomized, double blind, placebo-controlled study                                                                                   Children age 1--12 y with fever (\>100°F \[\>38°C\]) and a history of cough or coryza \<48 hours' duration                                       NA                                                         ([@R21])

\*CI, confidence interval; NA, not applicable; HR, hazard ratio; OR, odds ratio; RR, relative risk.

Calculating Ranges and Sensitivity Analyses
-------------------------------------------

For each level of antiviral effectiveness (lower, upper), and for each age group, we calculated the median and lower and upper estimates of hospitalizations averted. We also conducted sensitivity analyses by altering from 0% to 30% the assumed percentages of prescriptions written for prophylaxis, personal stockpiles, and patients who did not adhere to the drug regimen.

Results
=======

Pandemic influenza vaccine became available in week 40 of 2009 (near the peak of cases). We hypothesized that before this date is when doctors would have been most likely to try to protect patients by prescribing prophylactic courses of antiviral drugs. However, the plot of the prescription data against estimated cases over time shows a close correlation between the occurrence of pandemic (H1N1) 2009 clinical cases and filled prescriptions ([Table 1](#T1){ref-type="table"}; [Figure](#F1){ref-type="fig"}). This comparison suggests that antiviral drugs were mostly prescribed to treat the occurrence of clinical cases of pandemic (H1N1) 2009.

![Number of estimated influenza cases and filled prescriptions for influenza antiviral drugs during pandemic (H1N1) 2009 in the United States, September 2009--March 2010. The estimates of cases for April--August 2009 are not available on a weekly basis. During April 12--July 23, 2009, there were 3.1 million cases and 1.3 million prescriptions filled for influenza antiviral drugs. For the month of August 2009, there were 1.6 million cases and 354,000 prescriptions filled for influenza antiviral drugs. Estimates of cases from Shrestha et al. ([@R1]); number of prescriptions filled from the IMS Health Xponent database ([@R3]).](11-0295-F){#F1}

The total number of prescriptions filled before adjustments was 8.2 million ([Table 1](#T1){ref-type="table"}). After removing the prescriptions presumed filled for prophylaxis and for patients who failed to adhere to the drug regimen or had prescriptions filled for personal stockpiles, 5.7 million prescriptions were filled that may have reduced hospitalizations ([Table 4](#T4){ref-type="table"}). Most (97%) were filled for oseltamivir, and ≈55% of all prescriptions filled were for persons 18--64 years of age, and ≈40% were filled for children 0--17 years of age.

###### Estimated number of influenza antiviral drugs prescribed for treatment, after adjusting for prescriptions for prophylaxis, nonadherence, and personal stockpiling, pandemic (H1N1) 2009 outbreak, United States

  Influenza antiviral drug\*   No. prescriptions, by patient age group†   Total                 
  ---------------------------- ------------------------------------------ ----------- --------- -----------
  Oseltamivir                  2,152,915                                  2,979,711   297,700   5,430,326
  Zanamivir                    57,065                                     78,980      7,891     143,936
  Subtotal‡                    2,209,980                                  3,058,690   305,591   5,574,262

\*These antiviral drugs were prescribed in a variety of forms (e.g., capsules, tablets, syrup, and inhaled powder). The estimated numbers came from the IMS database ([@R3]), which records ≈73% of all prescriptions filled by \>50,000 US-based retail pharmacies. IMS then proportionately extrapolates their data, based on populations served by pharmacies, to provide weekly estimates of all prescriptions filled in the U.S. for these drugs. The IMS Health Xponent database does not cover in-hospital prescriptions. †These subtotals, by age group, are the estimates of prescriptions filled to treat pandemic (H1N1) 2009--related clinical illness, after removing the prescriptions filled for prophylaxis and for patients who failed to adhere to drug regimen or prescriptions filled for personal stockpiles (see [Table 1](#T1){ref-type="table"}). The total number of prescriptions filled, before adjustments, was 8,177,542 ([Table 1](#T1){ref-type="table"}). Note that ≈3% of prescriptions filled during this period did not have age of patient recorded, and we omitted those prescriptions from our calculations. ‡These subtotals, by age group, were the estimates used to calculate the hospitalizations averted as shown in [Table 5](#T5){ref-type="table"}.

We estimated that the median number of hospitalizations averted ranged from 8,427 (lower 6,961; upper 9,479) to 12,641 (lower 10,442; upper 14,219) ([Table 5](#T5){ref-type="table"}). Approximately 60% of averted hospitalizations were among persons 18--64 years old. The estimated hospitalizations averted in children and adults \>65 years of age ([Table 5](#T5){ref-type="table"}) were similar. Although adults \>65 years of age received only ≈5% of filled prescriptions ([Table 4](#T4){ref-type="table"}), these prescriptions had a relatively substantial impact in averting hospitalizations because the risk for hospitalization is higher in this age group than the other risk groups ([Table 2](#T2){ref-type="table"}).

###### Estimates of hospitalizations averted, by age group, assuming lower and upper estimates of influenza antiviral drug effectiveness, United States, 2009--2010\*

  Drug effectiveness estimate   No. hospitalizations averted, by patient age group, y, median (range)                                                 
  ----------------------------- ----------------------------------------------------------------------- ---------------------- ---------------------- -------------------------
  Lower                         1,848 (1,527--2,081)                                                    5,158 (4,264--5,803)   1,421 (1,171--1,595)   8,427 (6,961--9,479)
                                                                                                                                                      
  Upper                         2,687 (2,221--3,027)                                                    7,586(6,270--8,534)    2,368 (1,951--2,659)   12,641 (10,442--14,219)

\*Estimates of antiviral drug effectiveness are shown [Table 2](#T2){ref-type="table"} (source, [Table 1](#T1){ref-type="table"}). Lower, median, and upper estimates are generated by using the range of age-specific probabilities of hospitalization, given influenza-related clinical illness ([Table 2](#T2){ref-type="table"}).

Doubling the assumed percentages of filled prescriptions for prophylaxis and personal stockpiles/nonadherence from 30% to 60% (i.e., a 100% increase) produced only a 40% reduction in median hospitalizations averted, from ≈12,600 to 7,200 ([Table 6](#T6){ref-type="table"}). Thus, the major factors influencing hospitalizations averted were total prescriptions filled and (assumed) effectiveness of the drugs in preventing hospitalizations.

###### Sensitivity analysis, altering the assumed percentage of prescriptions written for prophylaxis, nonadherence to drug regimen, and stockpiling, United States 2009--2010\*

  \% Prescriptions written for prophylaxis   \% Prescriptions resulting in nonadherence + stockpiling   Net no. prescriptions used to treat clinically diagnosed influenza   Median no. hospitalizations averted, by patient age group, y†                    
  ------------------------------------------ ---------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------- -------- ------- --------
  0                                          0                                                          8,177,542                                                            3,839                                                           10,837   3,383   18,059
  10                                         10                                                         6,542,034                                                            3,071                                                           8,669    2,707   14,447
  \>10                                       \>20                                                       5,724,279                                                            2,687                                                           7,586    2,368   12,641
  20                                         20                                                         4,906,525                                                            2,303                                                           6,502    2,030   10,835
  20                                         30                                                         4,088,771                                                            1,920                                                           5,418    1,692   9,030
  30                                         30                                                         3,271,017                                                            1,536                                                           4,335    1,353   7,224

\*Baseline data used displays 10% for prophylaxis and 20% for personal stockpiling and non-adherence. This baseline assumption was used to generate results in [Table 5](#T5){ref-type="table"}. †Results of sensitivity analysis were calculated by using the upper median estimates of antiviral effectiveness in preventing hospitalization among the clinically ill ([Table 1](#T1){ref-type="table"}, [Table 2](#T2){ref-type="table"}).

Discussion
==========

The close correlation between estimated pandemic influenza cases and filled prescriptions ([Figure](#F1){ref-type="fig"}) can be used as evidence that antiviral drugs were mostly used to treat those who were clinically ill (i.e., recommendations regarding use were essentially followed). Restricting the use of antiviral drugs to treating the clinically ill meant that preventing clinical cases from deteriorating into severe cases requiring hospitalizations was likely to have been among the major effects of antiviral drug use. By our estimates, this strategy worked; ≈8,000--13,000 hospitalizations were averted ([Table 5](#T5){ref-type="table"}). This reduction is equivalent to ≈4--5% of the total estimated pandemic (H1N1) 2009--related hospitalizations ([@R1]).

We found no other studies with which to compare our methods and results. We compared the accuracy of the IMS database using unpublished data from the Behavioral Risk Factor Surveillance System (BRFSS), conducted in 49 states (excluding Vermont, the District of Columbia, and Puerto Rico). From September 1, 2009, through March 31, 2010, adults (\>18 years old) responding to the BRFSS telephone survey were asked whether they had influenza-like illness (ILI) (defined as having had a fever with cough or sore throat) in the month preceding the interview. They were also asked if they sought medical care for their ILI condition and if they were prescribed antiviral drugs to treat their illnesses. Extrapolating the results to the national level in the period covered by the survey, we found that ≈54 million adults reported having ILI symptoms. Of those who reported having ILI and sought medical care, 4.1 million adults reported they were prescribed influenza antiviral drugs (oseltamivir or zanamivir) during August 2009--March 2010. The IMS database recorded 6.86 million prescriptions in the same period ([Table 1](#T1){ref-type="table"}); ≈40% for those 0--17 years of age ([Table 2](#T2){ref-type="table"}), leaving ≈4.1 million filled prescriptions for adults. This estimate is close to the number recorded by the BRFSS survey and further supports the idea that few prescriptions were for prophylaxis or personal stockpiles.

There are many limitations to this study; the biggest is the uncertainty regarding the effectiveness of the drugs in preventing hospitalizations. The effectiveness of the drugs in reducing risk for hospitalization caused by pandemic (H1N1) 2009 may vary considerably from estimates reported for nonpandemic strains of influenza virus. The data are also limited in that we cannot verify if those persons who filled a prescription were actually clinically ill from pandemic (H1N1) 2009 or to what extent they adhered to the drug regimen. We addressed this issue by allowing a wide range in drug effectiveness and a relatively large percentage of prescriptions filled for conditions other than direct treatment of pandemic (H1N1) 2009.

We were unable, because the available literature did not contain sufficiently reliable estimates of effectiveness of antiviral drugs against death, to estimate the number of deaths averted by treatment with antiviral drugs. Shrestha et al. ([@R1]) estimated that deaths caused by pandemic (H1N1) 2009 were equivalent to 1.5% of children's hospitalizations and 6% of hospitalizations for persons of all other ages. Assuming that hospitalizations averted generate similar percentages of deaths averted, then the use of antiviral drugs prevented 27--40 deaths in children 0--17 years of age and 395--597 deaths in adults of all ages (using median values of hospitalizations averted; [Table 4](#T4){ref-type="table"}).

If during the next pandemic there is a desire to produce better quality estimates (perhaps even produce estimates at regular intervals during the event), then additional data collection systems must be developed to overcome some of these limitations. For example, measuring the number of prescriptions filled for prophylaxis or personal stockpiles or degree of adherence can only reliably be conducted by interviewing patients and physicians. Improving estimates of impact of filled prescriptions in reducing adverse health outcomes during an event will require a large case--control study. Policy makers will have to determine if the value of such information warrants the investment in such data collection systems.

Our results also highlight how the use of influenza antiviral drugs during a pandemic is likely to be beneficial, notably through a presumed reduction in the demand for hospital-based resources. Reduced demand will also reduce costs of hospitalizations. Assuming a cost per influenza-related hospitalization of US\$5,000--\$7,000 per patient admitted (adjusted to 2009 dollars) ([@R22]--[@R26]), averted hospitalizations saved ≈\$42 million to \$88 million (based on median values of hospitalizations averted; [Table 4](#T4){ref-type="table"}). A detailed cost-effectiveness analysis, including an in-depth consideration of the costs of hospitalizing pandemic (H1N1) 2009 patients, is the subject of a separate analysis.

If the next influenza pandemic causes greater numbers of severe cases and hospitalizations than in 2009, there may be an increased demand for antiviral drugs for treatment and prophylaxis. Such increased demand could overwhelm the existing commercial distribution chains. Therefore, public health officials should consider these estimates as an indication of success of treating patients during the 2009 pandemic and a warning for the need for renewed planning to cope with the next pandemic.

Supplementary Material
======================

###### Technical Appendix

Estimating the impact of antiviral usage during 2009 influenza A (H1N1) pandemic.
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